Treatment for pediatric Hodgkin lymphoma with reduced chemotherapy and radiation
Official title: Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy.
Run by Hospital JP Garrahan · NCT03500133 · Data updated 2026-11-12
This study is testing a new way to treat children with Hodgkin lymphoma by using less chemotherapy and radiation to see if it can still help them get better while lowering the chances of long-term side effects.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 2 Years to 18 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Hospital JP Garrahan Government |
| Drugs / interventions | chemotherapy, radiation, doxorubicin |
| Locations | 1 site (Buenos Aires, Buenos Aires F.D.) |
| Status | Recruiting |
| Started | October 6, 2017 |
| Main results expected | October 31, 2027 |
| Study ends | October 31, 2032 |
| Registry record updated | April 16, 2025 |
| Trial ID | NCT03500133 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children and adolescents aged 2 to 18 years with newly diagnosed classical Hodgkin lymphoma.
✕Probably not a fit
Patients with lymphocyte predominant nodular Hodgkin lymphoma or those with immunodeficiencies may not benefit from this treatment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial aims to treat pediatric patients with newly diagnosed classical Hodgkin lymphoma by administering a tailored therapy that minimizes chemotherapy and radiation exposure. Patients are stratified into low, intermediate, and high-risk groups based on initial staging, followed by two courses of chemotherapy. Disease response is assessed early, allowing rapid responders to receive less treatment, while those who do not achieve complete remission may receive low-dose radiation. The goal is to achieve long-lasting remission while reducing the risk of late effects from treatment.
Why it matters
Potential benefit: If successful, this approach could lead to effective treatment of pediatric Hodgkin lymphoma with fewer long-term side effects.
How similar studies have gone: Previous studies have shown promise in reducing treatment intensity for Hodgkin lymphoma, but this specific approach is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histopathological diagnosis of classical Hodgkin lymphoma. * Normal renal, hepatic, pulmonary and metabolic function standards. * Informed consent signed by patient and/or legal caretakers. Exclusion Criteria: * Lymphocyte predominant nodular Hodgkin lymphoma * Any form of immunodeficiency before diagnosis. (primary immunodeficiencies, trasplant recipients or immunosuppressive therapies of any kind including corticoid therapies during 28 days before diagnosis). * Pregnancy and breastfeeding period. * Sexually active female patients who do not accept an effective contraceptive method during therapy. * Positive HIV serology. * Penfigus or hepatic ductopenia. * Hodgkin lymphoma as a secondary malignant disease.
Where it's running
-
Hospital JP Garrahan
Buenos Aires, Buenos Aires F.D., Argentina Recruiting
Study contacts
- Study coordinator: Pedro A Zubizarreta, MD
- Email: pedro.zubizarreta@hotmail.com
- Phone: +541131207433
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PET-guided first-line nivolumab plus chemotherapy for advanced Hodgkin lymphoma
This pilot trial tests whether adding nivolumab to initial chemotherapy and changing treatment based on an early PET scan helps adults with advanced classical Hodgkin lymphoma.
-
Evaluating Spectral CT for Cardiotoxicity in Lymphoma Patients Treated with Anthracyclines
This study is testing if a special type of CT scan can help find heart damage early in lymphoma patients who are being treated with certain chemotherapy drugs.
-
CD30-targeted bispecific-antibody‑armed autologous T-cell therapy for relapsed CD30-positive blood cancers
This treatment will try using a patient's own T cells armed with a CD30/CD3 bispecific antibody to treat adults with relapsed or refractory CD30-positive blood cancers.
-
Collecting biospecimens for cancer research
This study is collecting blood and tumor samples from adults with cancer to help researchers learn more about the disease and improve treatments.
-
Collecting tissue samples to study lymph cancer
This study is collecting tissue samples from people with lymphoid cancers to learn more about the disease and help create better treatments.
-
Collecting and reporting data on patients receiving stem cell transplants
This study is trying to gather and share information about patients getting stem cell transplants for blood cancers to better understand how well these treatments work.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.